Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398114 | 0.85 | KDM4E (0.41) | GAAKDM4EALDH1A1SMN1; SMN2HTR2A | |
| SCHEMBL4551089 | 0.85 | KDM4E (0.41) | GAANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2237186 | 0.84 | GAA (0.44) | GAANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2233817 | 0.84 | CYP3A4 (0.36) | GAAKDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL4543216 | 0.83 | HMGCR (0.40) | KDM4EALDH1A1TSHRCYP3A4MAPT | |
| SCHEMBL4551033 | 0.82 | HMGCR (0.39) | KDM4EALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL4405926 | 0.74 | HMGCR (0.42) | KDM4EALDH1A1TSHRTDP1CYP3A4 | |
| SCHEMBL5352148 | 0.73 | HTR2A (0.36) | ALDH1A1HTR2AHTR2CHTR2BTDP1 | |
| SCHEMBL4403250 | 0.71 | KDM4E (0.46) | GAAKDM4ESMN1; SMN2HTR2AHTR2C | |
| SCHEMBL2344974 | 0.70 | TRPV4 (0.36) | GAANPC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549651-B1 | PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS | WARNER LAMBERT CO (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7196090-B2 | Kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | GAA 1727/4885NPC1 2536/4885KDM4E 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.